By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Statin > Pravastatin

Pravastatin

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|614 words

Pravastatin: Drug Profile

What is Pravastatin?

Pravastatin is a prescription medication belonging to a class of drugs called statins, also known as HMG-CoA reductase inhibitors. It is primarily used to lower cholesterol levels and reduce the risk of cardiovascular disease in patients with high cholesterol or other heart disease risk factors. Pravastatin works by blocking an enzyme in the liver that produces cholesterol, helping to prevent heart attacks, strokes, and other cardiovascular complications.

Uses

Pravastatin is approved for several cardiovascular conditions:

  • High cholesterol (hypercholesterolemia): Reduces LDL (“bad”) cholesterol and total cholesterol levels while modestly increasing HDL (“good”) cholesterol
  • Primary prevention of heart disease: Prevents first-time heart attacks and cardiovascular events in people with elevated cholesterol and other risk factors
  • Secondary prevention after heart attack or stroke: Reduces risk of additional cardiovascular events in patients with established coronary heart disease
  • Mixed dyslipidemia: Treats abnormal blood lipid levels, including elevated triglycerides combined with high cholesterol
  • Familial hypercholesterolemia: Manages inherited conditions causing severely elevated cholesterol levels

How it works

Pravastatin works by inhibiting HMG-CoA reductase, a key enzyme responsible for cholesterol production in the liver. By blocking this enzyme, the medication reduces the liver’s ability to manufacture cholesterol, forcing the body to remove cholesterol from the bloodstream. This mechanism effectively lowers blood cholesterol levels and reduces the formation of arterial plaques that can lead to heart attacks and strokes.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Headache
  • Muscle aches or weakness
  • Nausea and digestive upset
  • Dizziness
  • Cold-like symptoms
  • Fatigue
  • Abdominal pain
  • Diarrhea

Serious side effects requiring immediate medical attention:

  • Severe muscle pain, tenderness, or weakness (potential rhabdomyolysis)
  • Dark-colored urine
  • Yellowing of skin or eyes (liver problems)
  • Severe abdominal pain
  • Memory problems or confusion

Warnings and precautions

  • Liver disease: Patients with active liver disease or unexplained elevated liver enzymes should not take pravastatin. Regular liver function monitoring may be recommended.
  • Pregnancy and breastfeeding: Pravastatin is contraindicated during pregnancy and breastfeeding as cholesterol is essential for fetal development.
  • Muscle disorders: Individuals with a history of muscle problems or taking certain medications that increase muscle injury risk should use pravastatin cautiously.
  • Kidney impairment: Patients with severe kidney disease may require dose adjustments or alternative treatments.
  • Alcohol consumption: Excessive alcohol use should be avoided as it may increase the risk of liver problems when combined with pravastatin.

Interactions

Pravastatin can interact with several medications and supplements:

  • Warfarin: May increase bleeding risk by enhancing warfarin’s effects, requiring more frequent blood clotting monitoring
  • Fibrates (gemfibrozil, fenofibrate): Increases risk of muscle damage when combined with statins
  • Niacin (high doses): May increase muscle toxicity risk, particularly when used in large therapeutic doses
  • Cyclosporine: Significantly increases pravastatin blood levels, requiring dose adjustments
  • Certain antibiotics (clarithromycin, erythromycin): May increase statin levels and muscle injury risk
  • Antifungal medications: Some antifungals can increase pravastatin concentration in the blood
  • Bile acid sequestrants: May reduce pravastatin absorption if taken simultaneously
  • Grapefruit juice: While less significant with pravastatin than other statins, large amounts may still affect drug levels

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosages for pravastatin range from 10 mg to 80 mg taken once daily, usually in the evening. The starting dose is commonly 40 mg daily, with adjustments based on cholesterol response and individual patient factors. For elderly patients or those with kidney impairment, lower starting doses of 10-20 mg daily may be appropriate. Maximum recommended dose is 80 mg daily. Dosage should always be determined and monitored by a healthcare provider based on individual cholesterol levels, cardiovascular risk factors, and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Pravastatin." GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/drug/pravastatin-4/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Why Women Choose Freebirth: What Research Reveals About Unattended Childbirth

A growing number of women are choosing unattended childbirth, driven by desire…

The Optimal Height for Elite Soccer Players: What Sports Science Reveals

Elite soccer demonstrates position-specific height selection rather than universal stature advantage. Analysis…

International Survey Reveals Critical Gaps in Cardio-Oncology Training Despite Rising Clinical Demand

An international survey presented at ESC Cardio-Oncology 2026 has identified substantial deficiencies…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Atorvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Lovastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Simvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Pitavastatin

By
Prof. Giorgi Pkhakadze
01/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up